| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/18/2001 | CA2377999A1 Compositions and methods for raising hdl cholesterol levels |
| 01/18/2001 | CA2377918A1 Compositions and methods for promoting nerve regeneration |
| 01/18/2001 | CA2376029A1 Use of pyridoxin derivatives for the treatment of diabetes and related complications |
| 01/18/2001 | CA2340757A1 Delivery of liposomal-encapsulated antioxidants and applications thereof |
| 01/17/2001 | EP1069124A1 2-Benzimidazolylamine compounds as ORL1-receptor agonists |
| 01/17/2001 | EP1068868A2 Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| 01/17/2001 | EP1068867A2 Pharmaceutical tablet comprising an NSAID and misoprostol |
| 01/17/2001 | EP1068799A2 Biological models capable of exhibiting secondary disease manifestations |
| 01/17/2001 | EP1068357A1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 01/17/2001 | EP1068338A2 Enhanced prodrug activation |
| 01/17/2001 | EP1068336A2 Membranemetalloprotease nepii |
| 01/17/2001 | EP1068236A1 Human oxidized ldl receptor |
| 01/17/2001 | EP1068224A2 Pharmaceuticals for the imaging of angiogenic disorders |
| 01/17/2001 | EP1068220A1 nrdF |
| 01/17/2001 | EP1068218A2 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| 01/17/2001 | EP1068195A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1068172A1 PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST |
| 01/17/2001 | EP1067972A1 Multicomponent complex for use with a substrate |
| 01/17/2001 | EP1067966A1 OPHTHALMIC COMPOSITION COMPRISING A $g(b)-BLOCKER |
| 01/17/2001 | EP1067965A1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma |
| 01/17/2001 | EP1067958A2 Treatment of cardiac hypertrophy |
| 01/17/2001 | EP1067953A1 Methods for treating an ischemic disorder and improving stroke outcome |
| 01/17/2001 | EP1067945A2 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| 01/17/2001 | EP1067944A1 New combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| 01/17/2001 | EP1067942A1 High-energy cyclodextrin complexes |
| 01/17/2001 | EP1067941A1 Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate |
| 01/17/2001 | EP1067940A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 01/17/2001 | EP1067932A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067931A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067930A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067929A1 Antagonists of gonadotropin releasing hormone |
| 01/17/2001 | EP1067928A1 Methods for inhibiting mrp1 |
| 01/17/2001 | EP1067926A2 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
| 01/17/2001 | EP1067925A1 Antidiabetic agents |
| 01/17/2001 | EP1067922A1 Agents and methods for modulation of zinc transfer by metallothionein |
| 01/17/2001 | EP1067920A1 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin |
| 01/17/2001 | EP1067917A2 Method of treating dopaminergic and gaba-nergic disorders |
| 01/17/2001 | EP1067916A2 Method for producing transdermal therapeutic systems by using basic alkali metal salts for converting active agent salts into free bases |
| 01/17/2001 | EP1067897A1 An acidified composition for topical treatment of nail and skin conditions |
| 01/17/2001 | EP1067893A2 Human galactosyl transferases |
| 01/17/2001 | EP0983258A4 N-hydroxy 4-sulfonyl butanamide compounds |
| 01/17/2001 | CN1280506A Oral Preparation |
| 01/17/2001 | CN1280505A Composition for treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant of anti-anxiety drug |
| 01/17/2001 | CN1280503A Method of mobilizing hematopoietic stem cells |
| 01/17/2001 | CN1280494A Agents for combating neospora spec |
| 01/17/2001 | CN1280008A Strong anti-oxidative composite capsule of grape seed extract OPC and its producing method |
| 01/17/2001 | CN1060679C Use of combination of angiotensin-converting enzyme inhibitor and calcium antagonist for treatment of proteinuria |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174910 Treating pathological symptoms of vascular proliferation disorders which can be reduced or inhibited by apoptosis, by administering at.sub.1(angiotensin) receptor antagonist compound such as valsartan, irbesartan, losatran etc. |
| 01/16/2001 | US6174904 Treating glycometabolism disorders in mammals by administering therapeutically effective amount of an insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor |
| 01/16/2001 | US6174890 A synergistic biological, neurometabolic and celltrophic composition comprising antioxidative and -catabolic stress (methionine),-anabolic drugs, vasodilative and normo-lipidemic drugs (nicotinic acid), energoactive and antitoxic |
| 01/16/2001 | US6174882 Treating psychosis, acute mania, schizophrenia, excessive agression, substance abuse and fungal dermatitis; bipolar, autistism, tic, functional bowel and attention deficit hyperactivity disorders, anxiolytic agents; antidepressants |
| 01/16/2001 | US6174878 Topical use of kappa opioid agonists to treat otic pain |
| 01/16/2001 | US6174876 Use of boswellic acid for treating brain tumors |
| 01/16/2001 | US6174874 Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B) |
| 01/16/2001 | US6174857 Parenteral mixture comprising insulin-like growth factor i, a bone antiresorptive compound and a carrier |
| 01/16/2001 | US6174855 Pharmaceutical compositions comprising thrombin inhibitors and their use in the control of wound healing processes |
| 01/16/2001 | US6174714 Lyss |
| 01/16/2001 | US6174541 Promoting the healing of a tissue wound comprising delivering a therapeutically effective dosage of indole-3-acetic-acid or its derivatives |
| 01/16/2001 | US6174539 Localized use of nitric oxide adducts to prevent internal tissue damage |
| 01/16/2001 | CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists |
| 01/16/2001 | CA2204355C Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof |
| 01/14/2001 | CA2277407A1 Pharmaceutical tablet comprising an nsaid and misoprostol |
| 01/11/2001 | WO2001002866A1 Diagnostics and therapeutics for arterial wall disruptive disorders |
| 01/11/2001 | WO2001002855A1 Prevention and treatment of amyloid-associated disorders |
| 01/11/2001 | WO2001002598A2 Screening for compounds modulating mitochondrial proton leak |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002567A1 16405 receptor, a g-protein coupled receptor |
| 01/11/2001 | WO2001002561A2 Mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | WO2001002560A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002552A2 Double transgenic animals as models for neurodegenerative disease |
| 01/11/2001 | WO2001002551A2 Virus like particles, preparation and use in screening and functional genomics |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002549A2 Homomeric and heteromeric ampa receptors |
| 01/11/2001 | WO2001002478A1 Pre-formed, self-adhesive sheet devices suitable for topical application |
| 01/11/2001 | WO2001002443A1 Heparin compositions that inhibit clot associated coagulation factors |
| 01/11/2001 | WO2001002411A1 SULFONAMIDOMETHYL PHOSPHONATE INHIBITORS OF β-LACTAMASE |
| 01/11/2001 | WO2001002376A1 Amino-alkyl derivatives |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002029A1 Agent for occluding blood vessels |
| 01/11/2001 | WO2001002016A1 Nasogastric enteral formulations |
| 01/11/2001 | WO2001002014A1 Medicinal compositions for treating colorectal cancer |
| 01/11/2001 | WO2001002011A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 01/11/2001 | WO2001002007A1 Method for enhancing an immune response |
| 01/11/2001 | WO2001001998A2 Treatment of endometriosis with antileukoprotease |
| 01/11/2001 | WO2001001996A1 Compositions and methods for treating or preventing osteoporosis |
| 01/11/2001 | WO2001001987A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | WO2001001986A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | WO2001001985A1 Antiviral therapy |
| 01/11/2001 | WO2001001974A2 Naaladase inhibitors in anxiety and memory disorders |
| 01/11/2001 | WO2001001973A2 Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | WO2001001972A2 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/11/2001 | WO2001001971A1 Use of cortisol antagonists in the treatment for heat failure |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001969A2 Methods of treating and/or suppressing weight gain |
| 01/11/2001 | WO2001001968A2 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | WO2001001963A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001962A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001950A1 Pre-formed gel sheet |